Chemomab Therapeutics Ltd.
CMMBHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeChemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Valued at $7.5M, CMMB is a micro-cap name in its sector. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Market Cap
$7.5M
Beta
0.74
P/E (TTM)
—
P/E (Fwd)
-34.33
EPS (TTM)
$-0.99
EPS (Fwd)
$-0.03
ROE
-82.2%
ROA
-46.3%
Cash
$6.7M
Total Debt
$0
Free CF
-$6.2M
52W Change
-68.3%
Annual Financials
Cash vs Debt
Where CMMB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CMMB finished 35.36% below its 150-day moving average ($1.81) and 34.64% below its 200-day moving average ($1.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CMMB overbought or oversold?
At the October 20, 2026 close, CMMB's RSI(14) was 29.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Chemomab Therapeutics Ltd. reports $6.7M in cash and $0 in total debt. Free cash flow is running at -$6.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -82.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Chemomab Therapeutics Ltd.'s trajectory.